Brian B. Avants1, Corey McMillan2, Philip A. Cook1, James C. Gee3, Murray Grossman2
1University of Pennsylvania, Philadelphia, PA, United States; 2Neurology, University of Pennsylvania, Philadelphia, PA, United States; 3Radiology, University of Pennsylvania, Philadelphia, PA, United States
We employ quantitative longitudinal neuroimaging to contrast cortical atrophy rates between controls and patients with Alzheimer's disease (AD) or frontotemporal degeneration (FTD) defined on the basis of autopsy-confirmed cerebrospinal fluid (CSF) values of tau:Abeta1-42 ratio. We demonstrate that unbiased quantification of specific cortical regions improves detection power over whole brain analysis in both AD and FTD.